Full text is available at the source.
Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews
Effects of semaglutide in people with obesity or overweight who do not have diabetes: a review of reviews
AI simplified
Abstract
Semaglutide induced an average weight loss of 11.71 kg in non-diabetic obese patients.
- Weight loss represented a 12.79% reduction in body weight among participants.
- Significant increases were observed in the rates of weight loss of ≥5%, ≥10%, ≥15%, and ≥20%.
- Waist circumference decreased by 9.39 cm, and BMI reduced by 4.27 kg/m².
- Systolic blood pressure decreased by 4.78 mmHg and diastolic blood pressure by 2.56 mmHg.
- Fasting blood glucose dropped significantly by 5.46 mmol/l, and quality of life scores improved by 1.7 points.
- Common adverse reactions included nausea, diarrhea, and constipation, with relative risks of 2.59, 1.77, and 2.07, respectively.
AI simplified